Genexine, Inc. (KOSDAQ:095700)

Genexine Statistics

Total Valuation

Genexine has a market cap or net worth of KRW 218.30 billion.

Market Cap	218.30B
Enterprise Value	n/a

Important Dates

The last earnings date was Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Genexine has 45.48 million shares outstanding.

Current Share Class	45.48M
Shares Outstanding	45.48M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	4.98%
Owned by Institutions (%)	3.51%
Float	37.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	37.59
PB Ratio	0.76
P/TBV Ratio	0.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.24.

Current Ratio	1.29
Quick Ratio	1.05
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-1.62
Interest Coverage	-11.39

Financial Efficiency

Return on equity (ROE) is -17.31% and return on invested capital (ROIC) is -6.98%.

Return on Equity (ROE)	-17.31%
Return on Assets (ROA)	-6.70%
Return on Invested Capital (ROIC)	-6.98%
Return on Capital Employed (ROCE)	-13.77%
Revenue Per Employee	67.53M
Profits Per Employee	-634.02M
Employee Count	86
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -13.50% in the last 52 weeks. The beta is 0.55, so Genexine's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	-13.50%
50-Day Moving Average	5,298.70
200-Day Moving Average	4,859.38
Relative Strength Index (RSI)	48.92
Average Volume (20 Days)	288,205

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genexine had revenue of KRW 5.81 billion and -54.53 billion in losses. Loss per share was -1,320.62.

Revenue	5.81B
Gross Profit	-196.75M
Operating Income	-43.18B
Pretax Income	-54.51B
Net Income	-54.53B
EBITDA	-38.14B
EBIT	-43.18B
Loss Per Share	-1,320.62

Balance Sheet

The company has 52.50 billion in cash and 68.67 billion in debt, giving a net cash position of -16.16 billion or -355.42 per share.

Cash & Cash Equivalents	52.50B
Total Debt	68.67B
Net Cash	-16.16B
Net Cash Per Share	-355.42
Equity (Book Value)	288.07B
Book Value Per Share	6,949.76
Working Capital	14.87B

Cash Flow

In the last 12 months, operating cash flow was -34.02 billion and capital expenditures -8.28 billion, giving a free cash flow of -42.30 billion.

Operating Cash Flow	-34.02B
Capital Expenditures	-8.28B
Free Cash Flow	-42.30B
FCF Per Share	-930.15

Margins

Gross Margin	-3.39%
Operating Margin	-743.54%
Pretax Margin	-938.51%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Genexine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.23%
Shareholder Yield	-21.23%
Earnings Yield	-24.98%
FCF Yield	-19.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 11, 2023. It was a forward split with a ratio of 1.3.

Last Split Date	Jan 11, 2023
Split Type	Forward
Split Ratio	1.3

Scores

Genexine has an Altman Z-Score of 2.63 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.63
Piotroski F-Score	2